Anemia and Chronic Kidney Disease Research
Nuclear receptors and other receptors are targets for anemia and chronic kidney disease research due to their involvement in the signaling pathways for metabolism, immune response, and inflammation. Understanding the mechanisms underlying the involvement of various receptors in the pathogenesis of certain anemias and chronic kidney disease, as well as the complications and comorbidities that result from it may oﬀer targets for the development of new treatments.
Specific receptors that are implicated as promising therapeutic targets for drug discovery in anemia and renal disease research include:
- AR (NR3C4)
- ERα (NR3A1)
- ERRα (NR3B1)
- GR (NR3C1)
- PPARα (NR1C1)
- TRα (NR1A1)
- TRβ (NR1A2)
- VDR (NR1I1)
Our receptor specific assays are cell-based reporter assay systems. They feature engineered receptor-specific reporter cells prepared using our unique CryoMite™ process. Once thawed, reporter cells are ready for immediate use. Test compounds can be screened for agonist or antagonist activities against receptors.
INDIGO Biosciences works closely with clients to provide the appropriate reporter specific assays for their anemia and chronic kidney disease research. To empower confident decision-making throughout the discovery process, our technology generates clear single receptor or full-panel screening results. Employing a luminescence-based method and our proprietary CryoMite™ preservation process, we provide reproducible results lot-to-lot about the efficacy, potency, and selectivity of your compounds, plus comprehensive lab reports that include helpful graphics, summaries, and insights.
Anemia is a condition in which the blood has a low number of red blood cells. This resulting in reduced oxygen flow to the body. Anemia is the most common blood condition in the United Stated affecting almost 6% of the population. There are three main causes for anemia including, blood loss, lack of red blood cell production, and high rates of red blood cell apoptosis.
Symptoms may include fatigue, cold hands and feet, pale or yellow skin, shortness of breath, lightheadedness, or a fast heartbeat. Comorbidities of anemia are hypertension, hypothyroidism,Cancer, cardiovascular disease, rheumatologic disease, and chronic kidney disease.
Chronic kidney disease (chronic renal disease) includes a variety of conditions that damage the kidneys and decrease their functioning. As kidney disease progresses, less waste gets filtered out, and it can build to high levels. There is an increased risk for developing chronic kidney disease for those with a family history of kidney disease, as well as those with the comorbidities diabetes, high blood pressure, and cardiovascular disease. More than 37 million people in the United States may have chronic kidney disease.
There typically are no symptoms in the early stages of chronic kidney disease, but as kidney damage progresses, signs and symptoms can include, nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, more frequent urination, swelling of feet and ankles, persistent itching, chest pain, and shortness of breath. Complications of chronic kidney disease include, fluid retention, cardiovascular disease, anemia, decreased sex drive, damage to the CNS, decreased immune response, pericarditis, and end-stage kidney disease. Chronic kidney disease can be diagnosed using a blood test to measure the glomerular filtration rate or a urine test to check for albumin. Imaging tests, and kidney biopsy can also be performed to understand the type of kidney disease and how much damage has occurred to recommend treatment.
Once damage to the kidney has occurred it is permanent. Treatment of chronic kidney disease largely depends on the underlying cause, but usually consists of measures to help control signs and symptoms and slow the progression of the disease. If the disease progresses to end-stage kidney disease when less than 15% of the kidney is functioning, treatments to maintain health include dialysis and kidney transplantation.